| Symbol
| CNR2
| contributors: mct - updated : 15-12-2021
|
| HGNC name
| cannabinoid receptor 2 (macrophage)
|
| HGNC id
| 2160
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
|
| loss of function
|
combined deficiency of the CNR1 and CNR2 receptors protects against age-related bone loss by osteoclast inhibition  | |
| Susceptibility
|
to ostoporosis (low hip BMD) to immune thrombocytopenic purpura |
| Variant & Polymorphism
SNP
| increasing the risk of osteoporosis |
|
significant overrepresentation of the RR genotype and of the R allele was observed only for the chronic form of immune thrombocytopenic purpura children |
| 
|
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| osteoarticular | bone | | |
| molecular target for the diagnosis and treatment of osteoporosis and other bone diseases (antagonists of CNR2) | | metabolism | lipid | | |
| pharmacological manipulation of CB2R may provide therapeutic possibilities to treat metabolic diseases associated with lipid dysregulation |
| | | |
|
| extensive cardiomyocyte loss and confluent scar formation were found in Cnr2-/- mice accompanied by significantly increased apoptosis and left ventricular dysfunction when compared with Cnr2 +/+ mice |